目前，包括英国和马来西亚在内的一些国家表示愿意购买这种实验性抗病毒药物，日本正就购买其抗病毒药物Molnupiravir进行谈判。Original title: Merck & Co Inc(MRK.US) rose by more than 3% to an all-time high with a market capitalization of more than $210 billion!
Merck & Co Inc (MRK.US), which closed 8.37 per cent higher on Friday, continued to rise today, hitting an intraday high of $84.54 and is now up 3.16 per cent at $83.97, with a temporary turnover of $1.4 billion and a new market capitalization of $212.5 billion.
The two companies will plan to apply for emergency use authorization (EUA) for the drug after the company announced on Friday that molnupiravir, an oral anti-novel coronavirus drug jointly developed with Ridgeback Biotherapeutics, will reduce the hospitalization rate and risk of death of mild or moderate COVID-19 patients who participated in the drug trial by 50%.
At present, some countries, including the United Kingdom and Malaysia, have expressed their willingness to buy this experimental antiviral drug, and Japan is in negotiations to buy its antiviral drug Molnupiravir.
